Zoetis Inc. (NYSE:ZTS) Shares Purchased by Canandaigua National Bank & Trust Co.

Canandaigua National Bank & Trust Co. boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 27.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,236 shares of the company’s stock after acquiring an additional 1,580 shares during the quarter. Canandaigua National Bank & Trust Co.’s holdings in Zoetis were worth $1,179,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis during the 3rd quarter worth about $31,000. First Personal Financial Services purchased a new position in Zoetis during the third quarter worth about $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis during the third quarter valued at about $33,000. Dunhill Financial LLC raised its stake in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares during the period. Finally, Quarry LP lifted its holdings in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of ZTS opened at $165.76 on Tuesday. The firm has a market capitalization of $74.79 billion, a price-to-earnings ratio of 31.16, a PEG ratio of 2.91 and a beta of 0.89. The firm’s fifty day simple moving average is $173.07 and its 200-day simple moving average is $180.47. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same period last year, the firm earned $1.36 earnings per share. Zoetis’s quarterly revenue was up 11.6% on a year-over-year basis. Equities analysts forecast that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a $0.50 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 1.21%. The ex-dividend date is Tuesday, January 21st. Zoetis’s dividend payout ratio is currently 37.59%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on ZTS shares. Leerink Partners began coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Stifel Nicolaus boosted their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, JPMorgan Chase & Co. increased their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average target price of $215.22.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.